These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35299724)

  • 1. Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.
    Yeung MHY; Leung KL; Choi LY; Yoo JS; Yung S; So PK; Wong CM
    Front Pharmacol; 2021; 12():777395. PubMed ID: 35299724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.
    Simanenkova A; Fuks O; Timkina N; Islamova A; Sufieva D; Kirik О; Korzhevskii D; Vlasov T; Karonova T
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):265. PubMed ID: 39082364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.
    Krisanapan P; Sanpawithayakul K; Pattharanitima P; Thongprayoon C; Miao J; Mao MA; Suppadungsuk S; Tangpanithandee S; Craici IM; Cheungpasitporn W
    Diseases; 2024 Jan; 12(1):. PubMed ID: 38248365
    [No Abstract]   [Full Text] [Related]  

  • 8. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms.
    Kawanami D; Takashi Y
    Front Pharmacol; 2020; 11():967. PubMed ID: 32694999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
    Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
    Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
    Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
    Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.
    Trevella P; Ekinci EI; MacIsaac RJ
    Nephrology (Carlton); 2024 Aug; 29(8):457-469. PubMed ID: 39030739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.